Influence of Hospital Type on Outcomes of Patients With Acute Spontaneous Intracerebral Hemorrhage: A Population-Based Study

Genomics of stroke recovery and outcome

The understanding of genomics has improved tremendously during the last decades. The concept of recovery and outcome after stroke has also progressed during this time. However, the connection between genomics and stroke recovery has only begun to emerge in a more structural and comprehensive way. Different types of outcomes and recovery occur after stroke. This depends on domain of neurological deficit, severity, resilience, receptivity for rehabilitation measures, and concomitant morbidity. Methods for assessing stroke patients' prognosis depend on these factors. Different genetic approaches are possible and there is an increasing need for linking genetic findings to other omics as well as to clinically meaningful results. This review addresses recent advances and views in clinical genomics of stroke recovery and outcome in humans with focus on current and previous studies, concepts, and future perspectives.

Intracerebral haemorrhage - mechanisms, diagnosis and prospects for treatment and prevention

Intracerebral haemorrhage (ICH) is a devastating condition associated with high mortality and substantial residual disability among survivors. Effective treatments for the acute stages of ICH are limited. However, promising findings from randomized trials of therapeutic strategies, including acute care bundles that target anticoagulation therapies, blood pressure control and other physiological parameters, and trials of minimally invasive neurosurgical procedures have led to renewed optimism that patient outcomes can be improved. Currently ongoing areas of research for acute treatment include anti-inflammatory and haemostatic treatments. The implementation of effective secondary prevention strategies requires an understanding of the aetiology of ICH, which involves vascular and brain parenchymal imaging; the use of neuroimaging markers of cerebral small vessel disease improves classification with prognostic relevance. Other data underline the importance of preventing not only recurrent ICH but also ischaemic stroke and cardiovascular events in survivors of ICH. Ongoing and planned randomized controlled trials will assess the efficacy of prevention strategies, including antiplatelet agents, oral anticoagulants or left atrial appendage occlusion (in patients with concomitant atrial fibrillation), and optimal management of long-term blood pressure and statin use. Together, these advances herald a new era of improved understanding and effective interventions to reduce the burden of ICH.